◀ Back to JUN
JUN — PPARG
Pathways - manually collected, often from reviews:
-
NCI Pathway Database Calcineurin-regulated NFAT-dependent transcription in lymphocytes:
NFAT1-c-4/PPARG complex (NFATC1_NFATC2_NFATC3-PPARG)
→
JUN/FOS/NFAT1-c-4 complex (FOS-JUN-NFATC1_NFATC2_NFATC3)
(transcription, inhibits)
Yang et al., J Biol Chem 2000
Evidence: reporter gene
-
NCI Pathway Database Calcineurin-regulated NFAT-dependent transcription in lymphocytes:
PPARG (PPARG)
→
JUN/FOS/NFAT1-c-4 complex (FOS-JUN)
(modification, collaborate)
Yang et al., J Biol Chem 2000, Chung et al., Mol Pharmacol 2003
Evidence: reporter gene, physical interaction
-
NCI Pathway Database Calcineurin-regulated NFAT-dependent transcription in lymphocytes:
PPARG (PPARG)
→
JUN (JUN)
(modification, collaborate)
Yang et al., J Biol Chem 2000, Chung et al., Mol Pharmacol 2003
Evidence: reporter gene, physical interaction
-
NCI Pathway Database Calcineurin-regulated NFAT-dependent transcription in lymphocytes:
JUN/FOS/NFAT1-c-4 complex (FOS-JUN)
→
NFAT1-c-4/PPARG complex (NFATC1_NFATC2_NFATC3-PPARG)
(modification, collaborate)
Yang et al., J Biol Chem 2000, Chung et al., Mol Pharmacol 2003
Evidence: reporter gene, physical interaction
-
NCI Pathway Database Calcineurin-regulated NFAT-dependent transcription in lymphocytes:
NFAT1-c-4/PPARG complex (NFATC1_NFATC2_NFATC3-PPARG)
→
JUN (JUN)
(modification, collaborate)
Yang et al., J Biol Chem 2000, Chung et al., Mol Pharmacol 2003
Evidence: reporter gene, physical interaction
-
NCI Pathway Database Calcineurin-regulated NFAT-dependent transcription in lymphocytes:
NFAT1-c-4/PPARG complex (NFATC1_NFATC2_NFATC3-PPARG)
→
JUN/FOS/NFAT1-c-4 complex (FOS-JUN-NFATC1_NFATC2_NFATC3)
(transcription, inhibits)
Chung et al., Mol Pharmacol 2003
Evidence: reporter gene
Text-mined interactions from Literome
Uchimura et al., Hepatology 2001
:
PPAR gamma:RXR activation also did not
affect nuclear factor kappa B (NF-kappa B) nuclear translocation nor NF-kappa B and
activator protein 1 (AP-1) activation in the electrophoretic mobility-shift assay
Fahmi et al., Arthritis Rheum 2001
:
Similarly, in a
PPARgamma dependent manner, 15d-PGJ2 inhibited deltaMEKK-1 induced
AP-1- and NF-kappaB-luciferase reporter plasmid activation
Subbaramaiah et al., J Biol Chem 2001
(Arthritis...) :
The induction of
c-Jun by PMA was
blocked by
PPARgamma ligands
Wang et al., J Biol Chem 2002
(Inflammation) :
Furthermore, constitutive activation of
PPAR-gamma resulted in simultaneous repression of
AP-1 and NF-kappaB activity, which suggests that PPAR-gamma may reduce pro-inflammatory phenotypes via, at least in part, suppression of the AP-1 and NF-kappaB pathways
Salomonsson et al., Atherosclerosis 2003
:
Together, these data suggest that oxLDL decreases VEGFR-1 expression in macrophages, probably through a
PPARgamma dependent reduction in the
AP-1 transcriptional activity
Guo et al., Diabetes 2004
:
PPAR-gamma overexpression
inhibited TGF-beta 1-induced fibronectin expression as well as the activation of
AP-1 ... In conclusion, pioglitazone inhibits TGF-beta 1-induced fibronectin expression by inhibiting
AP-1 activation
dependent on
PPAR-gamma , while 15d-PGJ ( 2 ) acts through a dual mechanism independent of and dependent on PPAR-gamma activation in mouse mesangial cells
Hazra et al., J Biol Chem 2004
:
PPARgamma expression also
inhibits the activation markers such as the expression of alpha-smooth muscle actin, type I collagen, and transforming growth factor beta1 ; DNA synthesis ; and JunD binding to the activator protein-1 (AP-1) site and
AP-1 promoter activity
Konstantinopoulos et al., Int J Colorectal Dis 2007
(Adenocarcinoma...) :
Down-regulation of
PPAR gamma and induction of the CBP transcriptional coactivator can
augment NF-kappaB and
AP-1 transcriptional activities leading to up-regulation of COX-2 expression in colon adenocarcinoma cells
Dai et al., J Dermatol Sci 2008
:
These results suggest that
PPAR gamma regulates involucrin expression by controlling the
AP-1 signal and p38 activation in 1 alpha,25 ( OH ) 2D3 induced keratinocyte differentiation
Riek et al., J Steroid Biochem Mol Biol 2010
(Atherosclerosis...) :
1,25 ( OH ) 2D3 downregulation of
c-Jun N-terminal kinase activation
reduced PPARgamma and CD36 expression, and prevented oxLDL derived cholesterol uptake